PT - JOURNAL ARTICLE AU - Christopher J. R. Illingworth AU - Alexandra Y. Kreins AU - Adriana Margarit-Soler AU - Tim Best AU - Patricia Dyal AU - Giovanna Lucchini AU - Kanchan Rao AU - Rachel Williams AU - Austen Worth AU - Judith Breuer TI - Within-host virus evolution during the extended treatment of RSV infection with mutagenic drugs AID - 10.1101/2022.09.02.22279474 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.02.22279474 4099 - http://medrxiv.org/content/early/2022/09/18/2022.09.02.22279474.short 4100 - http://medrxiv.org/content/early/2022/09/18/2022.09.02.22279474.full AB - Antiviral drugs causing viral mutagenesis have shown value against a broad range of RNA viruses causing respiratory illnesses. While drug-induced accumulation of mutations generally decreases viral fitness, the potential for mutagenesis to generate escape variants is unknown and concerns have been raised about adaptive evolution promoting drug-resistance. We report prolonged treatment of a life-threatening RSV infection with a combination of two viral RNA-dependent RNA polymerase (RdRp) inhibitors, ribavirin and favipiravir, in a child with severe combined immunodeficiency undergoing haematopoietic stem cell transplantation. Viral deep sequencing of longitudinally collected RSV samples determined that ribavirin caused a 3-fold increase in the viral mutation rate. There was no synergistic effect upon addition of favipiravir. Viral load remained unchanged throughout antiviral treatment, but genomic modelling predicted loss of viral fitness secondary to drug-induced mutagenesis. The viral changes coincided with stabilisation of the patient’s clinical condition. In the absence of viral clearance, adaptive evolution occurred on a complex fitness landscape, leading to increased population diversity at the haplotype level. The evolutionary consequences of using mutagenic antiviral drugs are likely to be hard to predict, but in this example within-host virus evolution under extended treatment with mutagenic drugs resulted in an overall loss of viral fitness due to deleterious mutations accumulating faster than could be outweighed by positive selection. These genomic findings occurred in tandem with evidence of clinical improvement and are potentially associated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCJRI acknowledges UKRI Medical Research Council funding (MC_UU_12014). AYK is supported by the Wellcome Trust (222096/Z/20/Z). This work was supported in part by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (grant numbers 101239/Z/13/Z and 101239/Z/13/A). We thank the patient, their family and the medical teams involved in their care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCL/UCLH Pathogen Biobank National Research Ethics Service Committee London Fulham (Research Ethics Committee reference: 12/LO/1089) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesViral sequence data are available from the Sequence Read Archive with accession number PRJNA846693.